News
Selection News
- 2024.03.26
- 「動画で観るシンバイオ製薬」を更新しました。(Japanese only)
- 2024.03.26
- 第19期定時株主総会の動画を掲載しました。(Japanese only)
- 2024.02.26
- Information on Shareholders' Meeting: Updated the Page
- 2024.02.20
- Article on 2023 Earnings Call Featured in Nikkei Biotech Online (Japanese only)
Source: Nikkei Biotech ONLINE, 2024.02.15
Although Nikkei BP grants permission to use the articles, the content of the articles does not constitute a recommendation to purchase/invest in a specific company/organization or product/service.
Unauthorized reproduction, duplication, or electronic storage of the articles/photos/charts, etc. is prohibited. - 2024.02.16
- 2023年12月期決算説明会の動画を掲載しました。(Japanese only)
- 2024.02.14
- 決算説明会資料（2023年12月期）(Japanese only)
- 2024.02.09
- Analyst Report[Full report] (Shared Research)
- 2024.01.16
- 株主様向け決算説明会への抽選によるご招待(Japanese only)
- 2023.11.17
- Notice of Relocation of Head Office
- 2023.11.14
- Analyst Report[Flash report] (Shared Research)
- 2023.11.06
- SymBio To Present Positive Data from Ongoing Phase 2a Study of IV Brincidofovir in Adenovirus Infection in Oral Presentation at the 65th American Society of Hematology (ASH) Annual Meeting
- 2023.10.12
- The Results of CRADA Study on Brincidofovir in Multiple Sclerosis Presented at the 9th Joint ECTRIMS-ACTRIMS Meeting
- 2023.07.20
- Notice of Personnel Changes at SymBio Pharma USA, Inc.
- 2023.07.07
- 株主様向け中間決算説明会への抽選によるご招待(Japanese only)
- 2023.06.12
- Presentation of the Results of Biomarker Research Predicting the Antitumor Effects of Brincidofovir at the 17th ICML
- 2023.05.29
- IV Brincidofovir in Adenovirus Infection achieved POC in Phase 2 Clinical Trial
- 2023.04.27
- Analyst Report[Flash report] (Shared Research)
- 2023.04.24
- SymBio enters into a CRADA to Assess Efficacy of Brincidofovir for Epstein-Barr Virus Associated Lymphoproliferative Disease
- 2023.03.28
- 「動画で観るシンバイオ製薬」を更新しました。(Japanese only)
- 2023.03.27
- 第18期定時株主総会の動画を掲載しました。(Japanese only)
- 2023.03.22
- Development of Brincidofovir for Multiple Sclerosis CRADA with the National Institute of Neurological Disorders and Stroke (NINDS)
- 2023.03.01
- 決算説明会質疑応答(Japanese only)
- 2023.02.17
- 2022年12月期決算説明会の動画を掲載しました。(Japanese only)
- 2023.02.14
- 決算説明会資料（2022年12月期）(Japanese only)
- 2023.02.09
- Analyst Report[Flash report] (Shared Research)
- 2023.01.16
- Analyst Report[Follow-up Report] (Fair Research)
- 2022.12.26
- SymBio files lawsuit against Pfizer Japan Inc. for infringement of TREAKISYM patents
- 2022.12.23
- 株主通信「SymBio VISION vol.22」
- 2022.12.16
- SymBio files lawsuit for infringement of TREAKISYM patents
- 2022.12.14
- SymBio Announces First Patient Dosed in Phase 2 Clinical Trial of Anti-viral Drug Brincidofovir IV in Australia
- 2022.12.13
- Presentation on the Anti-lymphoma Activity of Brincidofovir at the 64th ASH Annual Meeting
- 2022.11.24
- SymBio enters into Material Transfer Agreement with Penn State College of Medicine for a non-clinical study to evaluate the efficacy of brincidofovir in a polyomavirus model
- 2022.06.14
- SymBio submits clinical trial notification to PMDA for Phase 2 clinical trial of anti-viral drug brincidofovir IV for patients with BK virus infection after renal transplantation
- 2022.06.01
- Completion of Payment for the Issuance of New Shares and the 58th Stock Acquisition Rights through Third-party Allotment
- 2022.04.01
- Joint research agreement with the National Cancer Center on rare cancers
- 2022.03.08
- SymBio announces publication the final results of its phase 3 clinical trial of TREAKISYM in r/r DLBCL
- 2022.03.07
- SymBio announces initiation of non-clinical study of brincidofovir IV for brain tumors in collaboration with Brown University, USA
- 2022.02.28
- SymBio receives approval of TREAKISYM Liquid Formulation Rapid Infusion (RI) administration
- 2022.02.25
- Response to marketing approvals of generic products
- 2022.02.24
- SymBio announces results of a collaborative study with the National Institute of Infectious Diseases on adenoviruses and the antiviral agent brincidofovir
- 2022.01.18
- SymBio submits clinical trial application to MHRA for Phase 2 clinical trial of anti-viral drug brincidofovir IV for treatment of pediatric adenovirus infection
- 2021.11.11
- Message from President of SymBio Pharma USA
- 2021.09.08
- SymBio announces initiation of non-clinical study of brincidofovir IV at the Brain Tumor Center, Department of Neurological Surgery University of California, San Francisco
- 2021.09.01
- SymBio enters into a collaborative research agreement with the National Cancer Centre Singapore on Epstein-Barr virus positive lymphoma
- 2021.08.17
- SymBio Announces First Patient Dosed in Phase 2 Clinical Trial of anti-viral drug Brincidofovir IV
- 2021.06.07
- Chimerix receives U.S. Food and Drug Administration approval for brincidofovir for the treatment of smallpox
- 2021.04.28
- SymBio receives approval for use of TREAKISYM Ready-To-Dilute (RTD) Formulation in combination with rituximab and polatuzumab vedotin for treatment of relapsed or refractory diffuse large B-cell lymphoma
- 2021.04.28
- SymBio receives approval for use of TREAKISYM Ready-To-Dilute (RTD) Formulation in combination with rituximab for treatment of relapsed or refractory diffuse large B-cell lymphoma
- 2021.04.26
- U.S. Food and Drug Administration granted fast track designation to antiviral agent brincidofovir IV for the treatment of adenovirus infection in pediatric patients
- 2021.01.12
- Market Launch of TREAKISYM Ready-To-Dilute (RTD) Formulation
- 2018.07.30
- Revised Medical Practice Guidelines 2018 for Healthcare Professionals